EUVIMEDEUVIMED entdecken
Open Access

Severe Mycobacterial Immune Reconstitution Inflammatory Syndrome (IRIS) in Advanced Human Immunodeficiency Virus (HIV) Has Features of Hemophagocytic Lymphohistiocytosis and Requires Prolonged Immune Suppression

Joseph M Rocco iD, Elizabeth Laidlaw, Frances Galindo, Megan Anderson, Adam Rupert, Jeanette Higgins, Ornella Sortino, Ana M Ortega-Villa, Virginia Sheikh, Gregg Roby, Safia Kuriakose, Andrea Lisco und 2 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Joseph M Rocco und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Immune Reconstitution Inflammatory Syndrome, Lymphohistiocytosis, Hemophagocytic, HIV Infections. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS, Department of Health and Human Services, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with HIV and mycobacterial infections can develop immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral therapy (ART). Severe mycobacterial IRIS has an overlapping clinical phenotype with hemophagocytic lymphohistiocytosis (HLH). We evaluated the pathophysiologic similarities between mycobacterial IRIS and HLH to identify clinical and immune predictors of mycobacterial IRIS severity.

Methods

HLH criteria were applied to a longitudinal cohort of 80 patients with HIV (CD4 <100 cells/µL) and mycobacterial infections. Participants were subdivided into IRIS meeting HLH criteria (HLH-IRIS), IRIS without HLH (IRIS), and those without IRIS (non-IRIS). Clinical outcomes were evaluated by regression analyses. Soluble biomarkers and T-cell subsets were assessed at baseline and IRIS-equivalent time points.

Results

HLH-IRIS patients required corticosteroids more frequently (OR: 21.5; 95%CI: 5.6–114.8) and for longer duration (21.2; 95%CI: 10.7–31.7 weeks) than those not meeting HLH criteria. Utilizing decision tree analyses, hemoglobin <9.2 g/dL was the best predictor of HLH-IRIS before ART, whereas ferritin, CXCL9 and sCD25 were most diagnostic for HLH at IRIS onset. At the IRIS timepoint, but not baseline, HLH-IRIS patients had lower regulatory and higher activated T cells along with greater production of IFNγ–IL-18 axis biomarkers compared with both IRIS and non-IRIS groups. Principal component analysis corroborated the distinct clustering of HLH-IRIS patients.

Conclusions

Severe mycobacterial IRIS and HLH have an overlapping pathogenesis involving IFNγ and unopposed T-cell activation causing severe inflammatory disease clinically distinguished by hyperferritinemia (hyperferritinemic IRIS [FIRIS]). Hemoglobin, ferritin, CXCL9, and sCD25 identify high-risk patients and may improve risk stratification and therapeutic strategies for mycobacterial IRIS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Reconstitution Inflammatory SyndromeLymphohistiocytosis, HemophagocyticHIV InfectionsHumansHIVBiomarkers

Stichwörter der Autor:innen

human immunodeficiency virusimmune reconstitution inflammatory syndromemacrophage activation syndromemycobacteriatuberculosis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Leidos Biomedical Research, Inc, Frederick, Maryland, USA.

ORCID-Profile: Joseph M Rocco

Förderung

  • HHS
  • Department of Health and Human Services
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Rocco, J. M., Laidlaw, E., Galindo, F., Anderson, M., Rupert, A., Higgins, J., Sortino, O., Ortega-Villa, A. M., Sheikh, V., Roby, G., Kuriakose, S., Lisco, A., Manion, M., & Sereti, I. (2023). Severe Mycobacterial Immune Reconstitution Inflammatory Syndrome (IRIS) in Advanced Human Immunodeficiency Virus (HIV) Has Features of Hemophagocytic Lymphohistiocytosis and Requires Prolonged Immune Suppression. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac717

Vancouver

Rocco JM, Laidlaw E, Galindo F, Anderson M, Rupert A, Higgins J, et al. Severe Mycobacterial Immune Reconstitution Inflammatory Syndrome (IRIS) in Advanced Human Immunodeficiency Virus (HIV) Has Features of Hemophagocytic Lymphohistiocytosis and Requires Prolonged Immune Suppression. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac717

BibTeX
@article{Rocco2023,
  author = {Rocco, Joseph M and Laidlaw, Elizabeth and Galindo, Frances and Anderson, Megan and Rupert, Adam and Higgins, Jeanette and Sortino, Ornella and Ortega-Villa, Ana M and Sheikh, Virginia and Roby, Gregg and Kuriakose, Safia and Lisco, Andrea and Manion, Maura and Sereti, Irini},
  title = {Severe Mycobacterial Immune Reconstitution Inflammatory Syndrome (IRIS) in Advanced Human Immunodeficiency Virus (HIV) Has Features of Hemophagocytic Lymphohistiocytosis and Requires Prolonged Immune Suppression},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac717}
}
Kostenlos starten →